MediNatura recalled ClearLife Allergy Nasal Spray on December 12, 2025, due to microbial contamination. The product contains yeast, mold, and Achromobacter. Consumers should stop use immediately and contact healthcare providers.
Microbial Contamination of Non-Sterile Products: The products have been found to contain yeast/mold and microbial contamination identified as Achromobacter.
Consumers and healthcare providers should stop using this product immediately. Contact Medinatura New Mexico, inc. or your healthcare provider for guidance. Notification method: Two or more of the following: Email, Fax, Letter, Press Release, Telephone, Visit
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The ClearLife Allergy Nasal Spray, Extra Strength, comes in 0.68 fl. oz. (20 mL) bottles. It is distributed by MediNatura, located at 10421 Research Rd., SE, Albuquerque, NM 87123. The product has a National Drug Code (NDC) of 62795-4006-9 and a UPC of 787647101887.
The nasal spray has been found to contain yeast, mold, and microbial contamination identified as Achromobacter. This contamination poses a high risk to consumers, particularly those with weakened immune systems.
There have been no reported injuries or deaths associated with this recall. However, the presence of Achromobacter can lead to serious infections, especially in vulnerable populations.
Stop using the ClearLife Allergy Nasal Spray immediately. Contact MediNatura or your healthcare provider for guidance on next steps.
For more information, call MediNatura at the number provided on the product packaging. Additional details can be found at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=D-0289-2026.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.